Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

NCT03025945 NA COMPLETED Results posted

Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

Details

Lead sponsor	Intuor Technologies, Inc.
Phase	NA
Status	COMPLETED
Enrolment	662
Start date	2013-10
Completion	2017-01

Conditions

• Cystoid Macular Edema

Interventions

• Nepafenac 0.3%
• Saline Solution

Primary outcomes

• Post-operative Clinical Findings of Cystoid Macular Edema — 6 weeks
  post-operative macular volume (mm)